Gavreto (Pralsetinib) 100mg*60 | Blueprint Medicines USA | GLT

Generic Information: Gavreto (Pralsetinib) 100mg — United States

Gavreto is the originator brand of pralsetinib, a potent and highly selective RET kinase inhibitor discovered by Blueprint Medicines Corporation of the United States. Pralsetinib was developed specifically to target cancers driven by RET gene alterations — RET fusions and RET mutations — rather than the broader activity of earlier multi-kinase inhibitors. This listing is the US presentation, supplied as 100 mg capsules in a 60-capsule pack that matches the standard 400 mg once-daily regimen of four capsules per day.

Gavreto received accelerated approval from the FDA for metastatic RET fusion-positive non-small cell lung cancer, followed by approval for RET-altered thyroid cancers, based on response data from the ARROW study. Its selectivity for RET over other kinases is the key clinical distinction from older multi-targeted agents, which translates into a different tolerability and dosing profile.

What Is Gavreto Used For?

Gavreto treats adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, as well as adults and children aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer or RET-mutant medullary thyroid carcinoma (MTC) requiring systemic therapy. These RET-driven cancers are identified by molecular testing, and pralsetinib is one of the targeted therapies designed specifically for them.

How Does Gavreto Work?

Pralsetinib is a small-molecule inhibitor of the RET receptor tyrosine kinase. In RET fusion-positive or RET-mutant tumours, the RET pathway is abnormally activated and drives cell proliferation and survival. By selectively blocking RET and its downstream signalling, Gavreto interrupts this growth signal. Its high selectivity for RET — including RET alterations that confer resistance to earlier therapies — is what distinguishes it from less selective multi-kinase inhibitors.

Indications

• Metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adults, detected by an FDA-approved test.
• Advanced or metastatic RET fusion-positive thyroid cancer in adults and children 12 years and older requiring systemic therapy.
• Advanced or metastatic RET-mutant medullary thyroid carcinoma (MTC) in adults and children 12 years and older requiring systemic therapy.

Dosage and Administration

The recommended dose is 400 mg once daily, taken as four 100 mg capsules on an empty stomach — no food for at least 2 hours before and at least 1 hour after dosing. A 60-capsule pack therefore provides 15 days of therapy at the standard dose. Dosing may be modified for adverse reactions, and blood pressure, liver function and blood counts are monitored during treatment.

Side Effects

Common adverse reactions include fatigue, constipation, musculoskeletal pain, hypertension, diarrhoea and elevated liver enzymes. Pneumonitis/interstitial lung disease is a serious risk requiring prompt reporting of new or worsening respiratory symptoms. Hypertension should be controlled before and during therapy, and patients should report any visual or bleeding changes.

Storage

Store Gavreto at room temperature, below 30°C, in the original container, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT can source the originator Gavreto and its regional presentations for buyers who specifically require the Blueprint Medicines brand, with documentation for import and compliance. The US list price of pralsetinib is high — several thousand dollars per month — so GLT helps institutions and patients identify the most cost-effective compliant supply route, and provides clear, responsive ordering support from inquiry through delivery.

How to Order Gavreto from GLT

Contact GLT on WhatsApp at +86 15234153837 or email [email protected] to inquire about Gavreto 100 mg capsules. Specify your quantity and destination, and we confirm pricing, batch origin and the required export documentation before dispatch.

FAQ

Is Gavreto the original pralsetinib? Yes, Gavreto is the originator brand discovered by Blueprint Medicines; all other pralsetinib products are generics of it.

What is the standard dose? 400 mg once daily (four 100 mg capsules), taken on an empty stomach.

What does Gavreto treat? RET fusion-positive NSCLC and RET-altered thyroid cancers, including RET-mutant medullary thyroid carcinoma.